Notice2023-25572
Meeting of the Advisory Committee on Blood and Tissue Safety and Availability
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
November 20, 2023
Issuing agencies
Health and Human Services Department
Abstract
The U.S. Department of Health and Human Services is hereby giving notice that the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) will hold a virtual meeting. The meeting will be open to the public via webcast. The committee will discuss and vote on recommendations related to surge capacity for blood and blood products.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 222 (Monday, November 20, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 222 (Monday, November 20, 2023)]
[Notices]
[Page 80729]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-25572]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Advisory Committee on Blood and Tissue Safety and
Availability
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The U.S. Department of Health and Human Services is hereby
giving notice that the Advisory Committee on Blood and Tissue Safety
and Availability (ACBTSA) will hold a virtual meeting. The meeting will
be open to the public via webcast. The committee will discuss and vote
on recommendations related to surge capacity for blood and blood
products.
DATES: The meeting will take place virtually on January 11, 2024 from
approximately 9:00 a.m.--5:00 p.m. Eastern Time (ET). Meeting times are
tentative and subject to change. The confirmed times and agenda items
for the meeting will be posted on the ACBTSA web page at <a href="https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2024-01-11/index.html">https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2024-01-11/index.html</a> when this information becomes available.
FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal
Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS
Policy, Office of the Assistant Secretary for Health, Department of
Health and Human Services, Tower Building, 1101 Wootton Parkway,
Rockville, MD, 20852. Email: <a href="/cdn-cgi/l/email-protection#56171514020517163e3e2578313920"><span class="__cf_email__" data-cfemail="b9f8fafbedeaf8f9d1d1ca97ded6cf">[email protected]</span></a>. Phone: 202-795-7608.
SUPPLEMENTARY INFORMATION: On the day of the meeting, please go to
<a href="https://www.hhs.gov/live/index.html">https://www.hhs.gov/live/index.html</a> to view the meeting. The public
will have an opportunity to present their views to the ACBTSA by
submitting a written public comment. Comments should be pertinent to
the meeting discussion. Persons who wish to provide written public
comment should review instructions at <a href="https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2024-01-11/index.html">https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2024-01-11/index.html</a> and respond by midnight January 3, 2024, ET. Written
public comments will be accessible to the public on the ACBTSA web page
prior to the meeting.
Background and Authority: The ACBTSA is a discretionary Federal
advisory committee and is governed by the provisions of the Federal
Advisory Committee Act (FACA), Public Law 92-463, as amended (5 U.S.C.
app), which sets forth standards for the formation and use of advisory
committees. The ACBTSA functions to provide advice to the Secretary
through the Assistant Secretary for Health on a range of policy issues
to include: (1) Identification of public health issues through
surveillance of blood and tissue safety issues with national survey and
data tools; (2) identification of public health issues that affect
availability of blood, blood products, and tissues; (3) broad public
health, ethical, and legal issues related to the safety of blood, blood
products, and tissues; (4) the impact of various economic factors
(e.g., product cost and supply) on safety and availability of blood,
blood products, and tissues; (5) risk communications related to blood
transfusion and tissue transplantation; and (6) identification of
infectious disease transmission issues for blood, organs, blood stem
cells and tissues. The Committee has met regularly since its
establishment in 1997.
Dated: November 2, 2023.
James J. Berger,
Designated Federal Officer, Advisory Committee on Blood and Tissue
Safety and Availability, Office of Infectious Disease and HIV/AIDS
Policy.
[FR Doc. 2023-25572 Filed 11-17-23; 8:45 am]
BILLING CODE 4150-28-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on November 20, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.